Published in Protein Sci on March 01, 2003
Ras homolog enriched in brain (Rheb) enhances apoptotic signaling. J Biol Chem (2010) 1.01
Backbone dynamics in an intramolecular prolylpeptide-SH3 complex from the diphtheria toxin repressor, DtxR. J Mol Biol (2007) 0.84
MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph (1996) 39.73
A new generation of information retrieval tools for biologists: the example of the ExPASy WWW server. Trends Biochem Sci (1994) 28.36
Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation. Biochemistry (1994) 13.94
SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science (1991) 12.93
A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res (1987) 7.43
Structural basis for the binding of proline-rich peptides to SH3 domains. Cell (1994) 6.34
Experiment and theory highlight role of native state topology in SH3 folding. Nat Struct Biol (1999) 3.50
Efficient analysis of macromolecular rotational diffusion from heteronuclear relaxation data. J Biomol NMR (2000) 3.06
High-resolution crystal structures of tyrosine kinase SH3 domains complexed with proline-rich peptides. Nat Struct Biol (1994) 2.95
The folding transition state between SH3 domains is conformationally restricted and evolutionarily conserved. Nat Struct Biol (1999) 2.93
Solution structure of the SH3 domain of Src and identification of its ligand-binding site. Science (1992) 2.56
Practical introduction to theory and implementation of multinuclear, multidimensional nuclear magnetic resonance experiments. Methods Enzymol (1994) 1.88
Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Histol Histopathol (2002) 1.73
A novel peptide-SH3 interaction. EMBO J (1999) 1.61
SH3 domain recognition of a proline-independent tyrosine-based RKxxYxxY motif in immune cell adaptor SKAP55. EMBO J (2000) 1.50
S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol (1999) 1.49
Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res (1997) 1.42
Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res (1994) 1.32
Characterization of the backbone dynamics of folded and denatured states of an SH3 domain. Biochemistry (1997) 1.31
SH3 domains and drug design: ligands, structure, and biological function. Biopolymers (1997) 1.26
Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins. Proc Natl Acad Sci U S A (2001) 1.22
A novel conserved cochlear gene, OTOR: identification, expression analysis, and chromosomal mapping. Genomics (2000) 1.19
The peroxisomal membrane protein Pex13p shows a novel mode of SH3 interaction. EMBO J (2000) 1.14
Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis. J Biol Chem (1996) 1.10
Photosystem I, an improved model of the stromal subunits PsaC, PsaD, and PsaE. J Biol Chem (1999) 1.06
Three-dimensional solution structure of PsaE from the cyanobacterium Synechococcus sp. strain PCC 7002, a photosystem I protein that shows structural homology with SH3 domains. Biochemistry (1994) 1.04
Identification and characterization of an inner ear-expressed human melanoma inhibitory activity (MIA)-like gene (MIAL) with a frequent polymorphism that abolishes translation. Genomics (2001) 1.04
Solution structure of the SH3 domain from Bruton's tyrosine kinase. Biochemistry (1998) 1.03
Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res (1995) 1.02
The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold. EMBO J (2001) 1.01
Protein dynamics from NMR. Biochem Cell Biol (1998) 0.94
MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis. Rheumatology (Oxford) (1999) 0.94
Fdp, a new fibrocyte-derived protein related to MIA/CD-RAP, has an in vitro effect on the early differentiation of the inner ear mesenchyme. J Biol Chem (2000) 0.93
Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res (1989) 0.91
Sequence-specific 1H, 13C, and 15N assignment of the human melanoma inhibitory activity (MIA) protein. J Biomol NMR (2000) 0.85
[MIA ("melanoma inhibitory activity"). Biological functions and clinical relevance in malignant melanoma]. Hautarzt (1998) 0.85
Solution structure and dynamics of melanoma inhibitory activity protein. J Biomol NMR (2002) 0.84
The solution structure of photosystem I accessory protein E from the cyanobacterium Nostoc sp. strain PCC 8009. Biochemistry (1999) 0.84
Characterization of selected strongly and weakly invasive sublines of a primary human melanoma cell line and isolation of subtractive cDNA clones. Int J Cancer (1995) 0.82
Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy. Oncol Res (1999) 0.79
Separation of anisotropy and exchange broadening using (15)N CSA-(15)N-(1)H dipole-dipole relaxation cross-correlation experiments. J Magn Reson (2000) 0.78
NMR 15N relaxation of the insulin-like growth factor (IGF)-binding domain of IGF binding protein-5 (IGFBP-5) determined free in solution and in complex with IGF-II. Eur J Biochem (2001) 0.76
Lifeact: a versatile marker to visualize F-actin. Nat Methods (2008) 12.23
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature (2005) 8.53
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell (2002) 5.19
Bats host major mammalian paramyxoviruses. Nat Commun (2012) 4.15
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol (2007) 3.89
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res (2006) 3.00
Filamins: promiscuous organizers of the cytoskeleton. Trends Biochem Sci (2006) 2.79
MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer (2008) 2.76
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res (2009) 2.65
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res (2006) 2.62
Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol (2012) 2.59
Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis (2009) 2.54
Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol (2007) 2.50
High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle (2009) 2.11
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol (2011) 2.10
Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature (2010) 2.01
Clear cell sarcoma-like tumor with osteoclast-like giant cells in the small bowel: further evidence for a new tumor entity. Int J Surg Pathol (2005) 1.74
The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. EMBO J (2002) 1.72
Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle (2008) 1.71
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
Transient protein states in designing inhibitors of the MDM2-p53 interaction. Structure (2013) 1.63
Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res (2004) 1.61
Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci (2009) 1.60
Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS One (2012) 1.60
Multiparameter immunofluorescence on paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol (2006) 1.59
Integrin signaling in malignant melanoma. Cancer Metastasis Rev (2005) 1.58
Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle (2007) 1.55
Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle (2010) 1.52
Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol (2012) 1.50
Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res (2005) 1.49
Blockade of angio-associated migratory cell protein inhibits smooth muscle cell migration and neointima formation in accelerated atherosclerosis. J Am Coll Cardiol (2008) 1.43
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest (2013) 1.41
Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol (2011) 1.38
Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol (2003) 1.36
Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol (2005) 1.35
Expansion of the genetic code enables design of a novel "gold" class of green fluorescent proteins. J Mol Biol (2003) 1.34
Ultrafast spectroscopy reveals subnanosecond peptide conformational dynamics and validates molecular dynamics simulation. Proc Natl Acad Sci U S A (2002) 1.34
Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology (2005) 1.32
A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer. EMBO J (2003) 1.32
A mouse model for cystic biliary dysgenesis in autosomal recessive polycystic kidney disease (ARPKD). Hepatology (2005) 1.31
Picosecond conformational transition and equilibration of a cyclic peptide. Proc Natl Acad Sci U S A (2003) 1.31
Structure of the stapled p53 peptide bound to Mdm2. J Am Chem Soc (2011) 1.30
The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed Engl (2011) 1.30
Practical aspects of the 2D 15N-[1h]-NOE experiment. J Biomol NMR (2002) 1.29
Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. Angew Chem Int Ed Engl (2010) 1.29
Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro Oncol (2008) 1.27
Placental failure and impaired vasculogenesis result in embryonic lethality for neuropathy target esterase-deficient mice. Mol Cell Biol (2004) 1.27
Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. ChemMedChem (2008) 1.27
Protein kinase C-zeta-induced phosphorylation of Ser318 in insulin receptor substrate-1 (IRS-1) attenuates the interaction with the insulin receptor and the tyrosine phosphorylation of IRS-1. J Biol Chem (2004) 1.26
Microsatellite instability of selective target genes in HNPCC-associated colon adenomas. Oncogene (2005) 1.26
Protein folding and stability of human CDK inhibitor p19(INK4d). J Mol Biol (2002) 1.25
Epigenetic regulation of cancer growth by histone demethylases. Int J Cancer (2010) 1.23
Modulation of red cell glycolysis: interactions between vertebrate hemoglobins and cytoplasmic domains of band 3 red cell membrane proteins. Am J Physiol Regul Integr Comp Physiol (2004) 1.23
Protein solubility: sequence based prediction and experimental verification. Bioinformatics (2006) 1.23
Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer. Int J Cancer (2005) 1.20
Primitive neuroectodermal tumor (PNET) in the differential diagnosis of malignant kidney tumors. Pathol Res Pract (2002) 1.20
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov (2014) 1.19
Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer (2012) 1.18
Multiple colon carcinomas in a patient with Cowden syndrome. Int J Mol Med (2006) 1.17
Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol (2003) 1.17
MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma. Cell Mol Life Sci (2010) 1.16
Application of NMR in structural proteomics: screening for proteins amenable to structural analysis. Structure (2002) 1.15
Deficiency in the LIM-only protein Fhl2 impairs skin wound healing. J Cell Biol (2007) 1.13
The crystal structure of the non-liganded 14-3-3sigma protein: insights into determinants of isoform specific ligand binding and dimerization. Cell Res (2005) 1.13
Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants. Hum Genet (2005) 1.13
β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis. Histopathology (2012) 1.12
MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression. Int J Cancer (2011) 1.12
Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences. J Biol Chem (2005) 1.12
Molecular structure of the rod domain of dictyostelium filamin. J Mol Biol (2004) 1.12
Iron-induced expression of bone morphogenic protein 6 in intestinal cells is the main regulator of hepatic hepcidin expression in vivo. Gastroenterology (2009) 1.11
Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci U S A (2006) 1.11
Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer (2006) 1.11
Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors. PLoS One (2009) 1.10
Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer. Mod Pathol (2005) 1.10
Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab Invest (2003) 1.10
Epigenetic events in malignant melanoma. Pigment Cell Res (2007) 1.10
Cold atmospheric plasma (CAP) changes gene expression of key molecules of the wound healing machinery and improves wound healing in vitro and in vivo. PLoS One (2013) 1.09
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med (2005) 1.09
c-Abl phosphorylates Hdmx and regulates its interaction with p53. J Biol Chem (2008) 1.09
Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex. Chembiochem (2007) 1.09
Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis (2005) 1.09
Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterol (2003) 1.08
Backbone dynamics of green fluorescent protein and the effect of histidine 148 substitution. Biochemistry (2003) 1.08
Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol (2009) 1.08
Role of the ubiquitin-like protein Hub1 in splice-site usage and alternative splicing. Nature (2011) 1.07
1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity. Chem Biol Drug Des (2010) 1.07
Characterization of 14-3-3sigma dimerization determinants: requirement of homodimerization for inhibition of cell proliferation. Cell Cycle (2006) 1.07
Shugoshin is a Mad1/Cdc20-like interactor of Mad2. EMBO J (2011) 1.06
Ultrastructural cartilage abnormalities in MIA/CD-RAP-deficient mice. Mol Cell Biol (2002) 1.06
A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J Am Coll Cardiol (2006) 1.06
Cold atmospheric plasma, a new strategy to induce senescence in melanoma cells. Exp Dermatol (2013) 1.04
Rapid and efficient hydrophilicity tuning of p53/mdm2 antagonists. J Comb Chem (2010) 1.03
Fussel-15, a novel Ski/Sno homolog protein, antagonizes BMP signaling. Mol Cell Neurosci (2007) 1.03
Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res (2009) 1.02
Slow exchange in the chromophore of a green fluorescent protein variant. J Am Chem Soc (2002) 1.02